

# Darren K Mcguire

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/546379/publications.pdf>

Version: 2024-02-01

471  
papers

56,520  
citations

4942

84  
h-index

1280

225  
g-index

486  
all docs

486  
docs citations

486  
times ranked

42887  
citing authors

#	ARTICLE	IF	CITATIONS
1	Guideline Development for Medical Device Technology: Issues for Consideration. <i>Journal of Diabetes Science and Technology</i> , 2023, 17, 1698-1710.	1.3	2
2	Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial. <i>Sleep and Breathing</i> , 2023, 27, 669-672.	0.9	10
3	Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1352-1360.	0.8	26
4	Nicotine promotes vascular calcification via intracellular Ca <sup>2+</sup> -mediated, Nox5-induced oxidative stress, and extracellular vesicle release in vascular smooth muscle cells. <i>Cardiovascular Research</i> , 2022, 118, 2196-2210.	1.8	24
5	Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial. <i>European Heart Journal</i> , 2022, 43, 2958-2967.	1.0	28
6	Late outcome, therapy and systemic ventricular function in patients with a systemic right ventricle: data of the German National Register for Congenital Heart Defects. <i>Cardiology in the Young</i> , 2022, 32, 1235-1245.	0.4	2
7	General Anesthesia Leads to Underestimation of Regurgitation Severity in Patients With Secondary Mitral Regurgitation Undergoing Transcatheter Mitral Valve Repair. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2022, 36, 974-982.	0.6	8
8	Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine. <i>Diabetes Care</i> , 2022, 45, 204-212.	4.3	25
9	Platelet Abnormalities in CKD and Their Implications for Antiplatelet Therapy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 155-170.	2.2	24
10	Incorporation of natriuretic peptides with clinical risk scores to predict heart failure among individuals with dysglycaemia. <i>European Journal of Heart Failure</i> , 2022, 24, 169-180.	2.9	23
11	Carbamylated sortilin associates with cardiovascular calcification in patients with chronic kidney disease. <i>Kidney International</i> , 2022, 101, 574-584.	2.6	14
12	Mannose as a biomarker of coronary artery disease: Angiographic evidence and clinical significance. <i>International Journal of Cardiology</i> , 2022, 346, 86-92.	0.8	10
13	Non-targeted metabolomics identify polyamine metabolite acisoga as novel biomarker for reduced left ventricular function. <i>ESC Heart Failure</i> , 2022, 9, 564-573.	1.4	6
14	A systematic review and meta-analysis of murine models of uremic cardiomyopathy. <i>Kidney International</i> , 2022, 101, 256-273.	2.6	13
15	Prediction of procedural success of transcatheter mitral valve repair with normal and extended clip arms. <i>International Journal of Cardiovascular Imaging</i> , 2022, , 1.	0.7	1
16	Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58. <i>Diabetes Care</i> , 2022, 45, 938-946.	4.3	20
17	The year in cardiovascular medicine 2021: diabetes and metabolic disorders. <i>European Heart Journal</i> , 2022, 43, 263-270.	1.0	7
18	Celebrating The Next Generation of Cardiovascular Investigators. <i>Circulation</i> , 2022, 145, 91-93.	1.6	0

#	ARTICLE	IF	CITATIONS
19	Recognized Outstanding Reviewers for <i>Circulation</i> in 2021. <i>Circulation</i> , 2022, 145, 4-4.	1.6	33
20	Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58. <i>Diabetes Care</i> , 2022, 45, e27-e29.	4.3	10
21	Association between exercise frequency with renal and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk. <i>Cardiovascular Diabetology</i> , 2022, 21, 12.	2.7	11
22	Feasibility of Wearable-Based Remote Monitoring in Patients During Intensive Treatment for Aggressive Hematologic Malignancies. <i>JCO Clinical Cancer Informatics</i> , 2022, 6, e2100126.	1.0	3
23	The gut hormone glucose-dependent insulinotropic polypeptide is downregulated in response to myocardial injury. <i>Cardiovascular Diabetology</i> , 2022, 21, 18.	2.7	0
24	Phenomapping-Derived Tool to Individualize the Effect of Canagliflozin on Cardiovascular Risk in Type 2 Diabetes. <i>Diabetes Care</i> , 2022, 45, 965-974.	4.3	13
25	Chemokine CCL9 Is Upregulated Early in Chronic Kidney Disease and Counteracts Kidney Inflammation and Fibrosis. <i>Biomedicines</i> , 2022, 10, 420.	1.4	4
26	Use of Lipid-, Blood Pressureâ€“, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease. <i>JAMA Network Open</i> , 2022, 5, e2148030.	2.8	30
27	Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. <i>Nature Medicine</i> , 2022, 28, 591-598.	15.2	139
28	Glucose-derived posttranslational modification in cardiovascular disease. <i>Molecular Aspects of Medicine</i> , 2022, , 101084.	2.7	3
29	Diabetes Mellitus and the Heart. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2022, , .	0.6	1
30	Position Paper on Lipid Therapy in Patients with Diabetes Mellitus. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2022, , .	0.6	0
31	Effects of COPD on Left Ventricular and Left Atrial Deformation in Patients with Acute Myocardial Infarction: Strain Analysis Using Speckle-Tracking Echocardiography. <i>Journal of Clinical Medicine</i> , 2022, 11, 1917.	1.0	1
32	Sodium-Glucose Cotransporter 2 Inhibitors and Cardiac Remodeling. <i>Journal of Cardiovascular Translational Research</i> , 2022, 15, 944-956.	1.1	21
33	Influence of rivaroxaban compared to vitamin K antagonist treatment upon development of cardiovascular calcification in patients with atrial fibrillation and/or pulmonary embolism. <i>Clinical Cardiology</i> , 2022, 45, 352-358.	0.7	2
34	Ertugliflozin, renoprotection and potential confounding by muscle wasting. Reply to Groothof D, Post A, Gans ROB et al [letter]. <i>Diabetologia</i> , 2022, 65, 908-911.	2.9	0
35	Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes. <i>Cardiovascular Diabetology</i> , 2022, 21, 50.	2.7	8
36	Effects of empagliflozin on markers of calcium and phosphate homeostasis in patients with type 2 diabetes â€“ Data from a randomized, placebo-controlled study. <i>Bone Reports</i> , 2022, 16, 101175.	0.2	11

#	ARTICLE	IF	CITATIONS
37	Efficacy and Safety of ELOM-080 as Add-On Therapy in COVID-19 Patients with Acute Respiratory Insufficiency: Exploratory Data from the Prospective Placebo-Controlled COVARI Trial. <i>Advances in Therapy</i> , 2022, , 1.	1.3	0
38	Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials. <i>Circulation</i> , 2022, 145, 1460-1470.	1.6	97
39	<i>Circulation</i> Best Papers 2021. <i>Circulation</i> , 2022, 145, 1441-1442.	1.6	0
40	Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial. <i>Circulation</i> , 2022, 145, 1581-1591.	1.6	13
41	The Role of Vitamin D3 as an Independent Predicting Marker for One-Year Mortality in Patients with Acute Heart Failure. <i>Journal of Clinical Medicine</i> , 2022, 11, 2733.	1.0	3
42	Guidelines for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1849-1857.	1.2	34
43	2022 Beijing Winter Olympics: Spotlight on Cardiac Metabolism. <i>Circulation</i> , 2022, 145, 1561-1562.	1.6	0
44	Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure. <i>ESC Heart Failure</i> , 2022, 9, 2233-2238.	1.4	15
45	Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF. <i>Circulation</i> , 2022, 146, 808-818.	1.6	33
46	Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1829-1839.	2.2	23
47	Validation of the WATCHâ€œDM and TRSâ€œHF <sub>DM</sub> Risk Scores to Predict the Risk of Incident Hospitalization for Heart Failure Among Adults With Type 2 Diabetes: A Multicohort Analysis. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	10
48	Left-Sided Degenerative Valvular Heart Disease in Type 1 and Type 2 Diabetes. <i>Circulation</i> , 2022, 146, 398-411.	1.6	10
49	Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. <i>European Heart Journal</i> , 2022, 43, 2931-2945.	1.0	14
50	Early Changes in Estimated Glomerular Filtration Rate Post-initiation of Empagliflozin in EMPEROR-Reduced Heart Failure Trial. <i>Diabetologie Und Stoffwechsel</i> , 2022, , .	0.0	0
51	High Circulating Triglycerides Are Most Commonly a Marker of Ectopic Fat Accumulation: Connecting the Clues to Advance Lifestyle Interventions. <i>Circulation</i> , 2022, 146, 77-79.	1.6	5
52	The sodiumâ€œglucose coâ€œtransporterâ€œ2 inhibitor ertugliflozin modifies the signature of cardiac substrate metabolism and reduces cardiac <sc>mTOR</sc> signalling, endoplasmic reticulum stress and apoptosis. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 2263-2272.	2.2	20
53	Detailed stratified GWAS analysis for severe COVID-19 in four European populations. <i>Human Molecular Genetics</i> , 2022, 31, 3945-3966.	1.4	46
54	Prevention of CV outcomes in antihyperglycaemic drug-naïve patients with type 2 diabetes with, or at elevated risk of, ASCVD: to start or not to start with metformin. <i>European Heart Journal</i> , 2021, 42, 2574-2576.	1.0	11

#	ARTICLE	IF	CITATIONS
55	Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose cotransporter 2 inhibitor therapy in <sc>DECLARE-TIMI</sc> 58. <i>European Journal of Heart Failure</i> , 2021, 23, 1026-1036.	2.9	35
56	Effect of linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulfonylurea glimepiride on cardiovascular outcomes in Asians with type 2 diabetes: subgroup analysis of the randomized CAROLINA® trial. <i>Diabetology International</i> , 2021, 12, 87-100.	0.7	12
57	Guideline recommendations and the positioning of newer drugs in type 2 diabetes care. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 46-52.	5.5	103
58	Screen-detected atrial fibrillation predicts mortality in elderly subjects. <i>Europace</i> , 2021, 23, 29-38.	0.7	19
59	Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes. <i>JAMA Cardiology</i> , 2021, 6, 148.	3.0	625
60	Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. <i>New England Journal of Medicine</i> , 2021, 384, 117-128.	13.9	1,080
61	Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2021, 384, 129-139.	13.9	662
62	Gradient of Risk and Associations With Cardiovascular Efficacy of Ertugliflozin by Measures of Kidney Function. <i>Circulation</i> , 2021, 143, 602-605.	1.6	24
63	Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized <sc>CAROLINA</sc> trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 569-580.	2.2	18
64	Role of extracorporeal membrane oxygenation in critically ill COVID-19 patients and predictors of mortality. <i>Artificial Organs</i> , 2021, 45, E158-E170.	1.0	30
65	Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status. <i>Circulation</i> , 2021, 143, 337-349.	1.6	217
66	SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. <i>American Journal of Kidney Diseases</i> , 2021, 77, 94-109.	2.1	88
67	Trends in Hospitalizations for Heart Failure and Ischemic Heart Disease Among US Adults With Diabetes. <i>JAMA Cardiology</i> , 2021, 6, 354.	3.0	15
68	SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. <i>Diabetes</i> , 2021, 70, 1-16.	0.3	53
69	Dynamic handgrip exercise for the evaluation of mitral valve regurgitation: an echocardiographic study to identify exertion induced severe mitral regurgitation. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 891-902.	0.7	4
70	Lactic acidosis incidence with metformin in patients with type 2 diabetes and chronic kidney disease: A retrospective nested case-control study. <i>Endocrinology, Diabetes and Metabolism</i> , 2021, 4, e00170.	1.0	8
71	Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from <sc>DECLARE-TIMI</sc> 58. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 29-38.	2.2	28
72	Effects of Sotagliflozin Combined with Intensive Insulin Therapy in Young Adults with Poorly Controlled Type 1 Diabetes: The JDRF Sotagliflozin Study. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 59-69.	2.4	11

#	ARTICLE	IF	CITATIONS
73	Antihyperglycemic therapies and cardiovascular outcomes in patients with type 2 diabetes mellitus: State of the art and future directions. <i>Trends in Cardiovascular Medicine</i> , 2021, 31, 101-108.	2.3	5
74	Gaps in Evidence-Based Therapy Use in Insured Patients in the United States With Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease. <i>Journal of the American Heart Association</i> , 2021, 10, e016835.	1.6	31
75	Early risk markers for severe clinical course and fatal outcome in German patients with COVID-19. <i>PLoS ONE</i> , 2021, 16, e0246182.	1.1	7
76	Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 226-236.	1.4	6
77	Cardiovascular outcomes in patients at high cardiovascular risk with previous myocardial infarction or stroke. <i>Journal of Hypertension</i> , 2021, 39, 1602-1610.	0.3	5
78	The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus. <i>Diabetologia</i> , 2021, 64, 1226-1234.	2.9	15
79	Renal outcomes and blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk. <i>Journal of Hypertension</i> , 2021, 39, 766-774.	0.3	9
80	Gut-Derived Metabolite Indole-3-Propionic Acid Modulates Mitochondrial Function in Cardiomyocytes and Alters Cardiac Function. <i>Frontiers in Medicine</i> , 2021, 8, 648259.	1.2	39
81	Time on previous renal replacement therapy is associated with worse outcomes of COVID-19 in a regional cohort of kidney transplant and dialysis patients. <i>Medicine (United States)</i> , 2021, 100, e24893.	0.4	9
82	Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial. <i>Diabetologia</i> , 2021, 64, 1256-1267.	2.9	103
83	Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58. <i>Diabetes Care</i> , 2021, 44, 1159-1167.	4.3	25
84	Dapagliflozin, advanced chronic kidney disease, and mortality: new insights from the DAPA-CKD trial. <i>European Heart Journal</i> , 2021, 42, 1228-1230.	1.0	15
85	Cardiovascular Disease in Chronic Kidney Disease. <i>Circulation</i> , 2021, 143, 1157-1172.	1.6	680
86	Positioning newer drugs in the management of type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 139-140.	5.5	3
87	Meta-analyses of Results From Randomized Outcome Trials Comparing Cardiovascular Effects of SGLT2is and GLP-1RAs in Asian Versus White Patients With and Without Type 2 Diabetes. <i>Diabetes Care</i> , 2021, 44, 1236-1241.	4.3	37
88	Development and validation of optimal phenomapping methods to estimate long-term atherosclerotic cardiovascular disease risk in patients with type 2 diabetes. <i>Diabetologia</i> , 2021, 64, 1583-1594.	2.9	13
89	Biomarker-Based Risk Prediction of Incident Heart Failure in Pre-Diabetes and Diabetes. <i>JACC: Heart Failure</i> , 2021, 9, 215-223.	1.9	50
90	Loss of CASK Accelerates Heart Failure Development. <i>Circulation Research</i> , 2021, 128, 1139-1155.	2.0	11

#	ARTICLE	IF	CITATIONS
91	Differences in glycemic control between the treatment arms in cardiovascular outcome trials of type 2 diabetes medications do not explain cardiovascular benefits. <i>Journal of Pharmaceutical Policy and Practice</i> , 2021, 14, 35.	1.1	1
92	Proof of Concept: Measuring Aortic Annulus Resistance by Means of Pressure-Volume Curves During Balloon Inflation to Guide Transcatheter Aortic Valve Implantation. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 665029.	1.1	1
93	Quantitative Flow Ratio Is Related to Intraluminal Coronary Stenosis Parameters as Assessed with Optical Coherence Tomography. <i>Journal of Clinical Medicine</i> , 2021, 10, 1856.	1.0	10
94	Thromboembolic and Bleeding Events in COVID-19 Patients receiving Extracorporeal Membrane Oxygenation. <i>Thoracic and Cardiovascular Surgeon</i> , 2021, 69, 526-536.	0.4	18
95	Timely and individualized heart failure management: need for implementation into the new guidelines. <i>Clinical Research in Cardiology</i> , 2021, 110, 1150-1158.	1.5	18
96	Coronary plaque composition influences biomechanical stress and predicts plaque rupture in a morpho-mechanic OCT analysis. <i>ELife</i> , 2021, 10, .	2.8	13
97	Diabetes-Related Factors and the Effects of Ticagrelor Plus Aspirin in the THEMIS and THEMIS-PCI Trials. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2366-2377.	1.2	13
98	Platelet Function in CKD: A Systematic Review and Meta-Analysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 1583-1598.	3.0	26
99	Six Months Follow-Up of Patients with Invasive Mechanical Ventilation Due to COVID-19 Related ARDS. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 5861.	1.2	20
100	Elevated serum SDMA and ADMA at hospital admission predict in-hospital mortality of COVID-19 patients. <i>Scientific Reports</i> , 2021, 11, 9895.	1.6	18
101	ACE2 polymorphism and susceptibility for SARS-CoV-2 infection and severity of COVID-19. <i>Pharmacogenetics and Genomics</i> , 2021, 31, 165-171.	0.7	73
102	Incidence and clinical relevance of persistent iatrogenic atrial septal defect after percutaneous mitral valve repair. <i>Scientific Reports</i> , 2021, 11, 12700.	1.6	3
103	Kidney outcomes using a sustained $\geq 40\%$ decline in $\langle \text{sc} \rangle \text{eGFR} \langle / \text{sc} \rangle$ : A meta-analysis of $\langle \text{sc} \rangle \text{SGLT2} \langle / \text{sc} \rangle$ inhibitor trials. <i>Clinical Cardiology</i> , 2021, 44, 1139-1143.	0.7	20
104	Human and mouse non-targeted metabolomics identify 1,5-anhydroglucitol as SGLT2-dependent glycemic marker. <i>Clinical and Translational Medicine</i> , 2021, 11, e470.	1.7	8
105	Outcomes of Extracorporeal Membrane Oxygenation for Acute Respiratory Distress Syndrome in COVID-19 Patients: A Propensity-Matched Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 2547.	1.0	9
106	Cardiovascular disease in patients with chronic kidney disease. <i>Herz</i> , 2021, 46, 205-205.	0.4	8
107	Treating heart failure in patients with diabetes: The view of the cardiologist. <i>Diabetes Research and Clinical Practice</i> , 2021, 176, 108852.	1.1	2
108	Accuracy of dynamic three-dimensional magnetic resonance perfusion imaging for the detection of coronary artery disease in patients with reduced ejection fraction. <i>Imaging</i> , 2021, 13, 61-68.	0.3	0

#	ARTICLE	IF	CITATIONS
109	Bronchoalveolar lavage in patients with acute respiratory distress syndrome due to COVID-19. Internal Medicine Journal, 2021, 51, 965-967.	0.5	3
110	Lesion Geometry as Assessed by Optical Coherence Tomography Is Related to Myocardial Ischemia as Determined by Cardiac Magnetic Resonance Imaging. Journal of Clinical Medicine, 2021, 10, 3342.	1.0	2
111	Quantitative flow ratio (QFR) identifies functional relevance of non-culprit lesions in coronary angiographies of patients with acute myocardial infarction. Clinical Research in Cardiology, 2021, 110, 1659-1667.	1.5	8
112	Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community. Circulation, 2021, 144, 74-84.	1.6	34
113	The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58. Diabetes Care, 2021, 44, 1805-1815.	4.3	49
114	Cardiac, renal, and metabolic effects of sodium-glucose cotransporter 2 inhibitors: a position paper from the European Society of Cardiology ad hoc task force on sodium-glucose cotransporter 2 inhibitors. European Journal of Heart Failure, 2021, 23, 1260-1275.	2.9	36
115	Association of Glucose-Dependent Insulinotropic Polypeptide Levels With Cardiovascular Mortality in Patients With Acute Myocardial Infarction. Journal of the American Heart Association, 2021, 10, e019477.	1.6	2
116	Effects of Transcatheter Mitral Valve Repair Using MitraClip® Device on Sleep Disordered Breathing in Patients with Mitral Valve Regurgitation. Journal of Clinical Medicine, 2021, 10, 3332.	1.0	3
117	Towards living guidelines on cardiorenal outcomes in diabetes: A pilot project of the Taskforce of the Guideline Workshop 2020. Diabetes Research and Clinical Practice, 2021, 177, 108870.	1.1	4
118	Effects of empagliflozin on lipoprotein subfractions in patients with type 2 diabetes: data from a randomized, placebo-controlled study. Atherosclerosis, 2021, 330, 8-13.	0.4	10
119	Association Between Achieved 3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk. JAMA Cardiology, 2021, 6, 910.	3.0	52
120	Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure. Annals of Internal Medicine, 2021, 174, 1065-1072.	2.0	32
121	Effects of empagliflozin on erythropoiesis in patients with type 2 diabetes: Data from a randomized, placebo-controlled study. Diabetes, Obesity and Metabolism, 2021, 23, 2814-2818.	2.2	38
122	Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine, 2021, 385, 1451-1461.	13.9	2,143
123	Epigenetic Clocks Are Not Accelerated in COVID-19 Patients. International Journal of Molecular Sciences, 2021, 22, 9306.	1.8	21
124	Quantitative Flow Ratio Is Associated with Extent and Severity of Ischemia in Non-Culprit Lesions of Patients with Myocardial Infarction. Journal of Clinical Medicine, 2021, 10, 4535.	1.0	3
125	Syncope in a Middle-aged Man. JAMA Internal Medicine, 2021, 181, 1505.	2.6	1
126	In Vivo Study of Electromagnetic Interference With Cardiac Contractility Modulation Devices at Power Frequency. Journal of the American Heart Association, 2021, 10, e019171.	1.6	0



#	ARTICLE	IF	CITATIONS
127	GLP1 receptor agonists: from antihyperglycaemic to cardiovascular drugs. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 640-641.	5.5	2
128	Clinical course of COVID-19 patients needing supplemental oxygen outside the intensive care unit. <i>Scientific Reports</i> , 2021, 11, 2256.	1.6	35
129	Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study. <i>Cardiovascular Diabetology</i> , 2021, 20, 6.	2.7	42
130	Extracorporeal membrane oxygenation in patients with COVID-19: 1-year experience. <i>Journal of Thoracic Disease</i> , 2021, 13, 5911-5924.	0.6	3
131	Prevention of vascular calcification by the endogenous chromogranin A-derived mediator that inhibits osteogenic transdifferentiation. <i>Basic Research in Cardiology</i> , 2021, 116, 57.	2.5	3
132	Prevalence and Prognostic Implications of Diabetes With Cardiomyopathy in Community-Dwelling Adults. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1587-1598.	1.2	23
133	Interpreting Absolute and Relative Risk Reduction in the Context of Recent Cardiovascular Outcome Trials in Patients with Type 2 Diabetes. <i>Current Diabetes Reports</i> , 2021, 21, 45.	1.7	3
134	Patterns of Prescribing Sodium-Glucose Cotransporter-2 Inhibitors for Medicare Beneficiaries in the United States. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, .	0.9	27
135	Abstract P156: Intimal And Medial Calcification Underlie Differential Molecular Mechanisms. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, .	1.1	0
136	Glucagon-like peptide 1 levels predict cardiovascular risk in patients with acute myocardial infarction. <i>European Heart Journal</i> , 2020, 41, 882-889.	1.0	25
137	Development of the Metabolic Syndrome: Study Design and Baseline Data of the Lufthansa Prevention Study (LUPS), A Prospective Observational Cohort Survey. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2020, 128, 777-787.	0.6	2
138	Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET/TRANSCEND trials. <i>European Heart Journal</i> , 2020, 41, 231-238.	1.0	35
139	Trends in Aggregate Use and Associated Expenditures of Antihyperglycemic Therapies Among US Medicare Beneficiaries Between 2012 and 2017. <i>JAMA Internal Medicine</i> , 2020, 180, 141.	2.6	17
140	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2020, 41, 255-323.	1.0	2,811
141	Glomerular Filtration Rate and Associated Risks of Cardiovascular Events, Mortality, and Severe Hypoglycemia in Patients with Type 2 Diabetes: Secondary Analysis (DEVOTE 11). <i>Diabetes Therapy</i> , 2020, 11, 53-70.	1.2	18
142	Association of obesity with cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: Insights from TECOS. <i>American Heart Journal</i> , 2020, 219, 47-57.	1.2	45
143	Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study. <i>Diabetes Care</i> , 2020, 43, 468-475.	4.3	72
144	Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial. <i>European Journal of Heart Failure</i> , 2020, 22, 126-135.	2.9	67

#	ARTICLE	IF	CITATIONS
145	Glycated Hemoglobin, Prediabetes, and the Links to Cardiovascular Disease: Data From UK Biobank. <i>Diabetes Care</i> , 2020, 43, 440-445.	4.3	56
146	Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease. <i>Circulation</i> , 2020, 142, 2205-2215.	1.6	156
147	High cardiovascular risk of patients with type 2 diabetes is only partially attributed to angiographic burden of atherosclerosis. <i>Diabetes and Vascular Disease Research</i> , 2020, 17, 147916412095361.	0.9	5
148	The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. <i>Diabetes Care</i> , 2020, 43, 3007-3015.	4.3	45
149	Integrative Multi-Omics Analysis in Calcific Aortic Valve Disease Reveals a Link to the Formation of Amyloid-Like Deposits. <i>Cells</i> , 2020, 9, 2164.	1.8	15
150	Reliable Detection of Atrial Fibrillation with a Medical Wearable during Inpatient Conditions. <i>Sensors</i> , 2020, 20, 5517.	2.1	13
151	Post-cardiac injury syndrome after transcatheter mitral valve repair using MitraClip system: a case report. <i>European Heart Journal - Case Reports</i> , 2020, 4, 1-5.	0.3	5
152	Follow up of patients with severe coronavirus disease 2019 (COVID-19): Pulmonary and extrapulmonary disease sequelae. <i>Respiratory Medicine</i> , 2020, 174, 106197.	1.3	235
153	Recognized Outstanding Reviewers for <i>Circulation</i> in 2020. <i>Circulation</i> , 2020, 142, 1885-1886.	1.6	0
154	Car Seats with Capacitive ECG Electrodes Can Detect Cardiac Pacemaker Spikes. <i>Sensors</i> , 2020, 20, 6288.	2.1	12
155	Diabetes and cardiovascular disease: it's time to apply the evidence. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 586-588.	0.4	0
156	First-line treatment for type 2 diabetes: is it too early to abandon metformin?. <i>Lancet</i> , The, 2020, 396, 1705-1707.	6.3	22
157	Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial. <i>Lancet Diabetes and Endocrinology</i> , the, 2020, 8, 949-959.	5.5	41
158	Prognostic irrelevance of plaque vulnerability following plaque sealing in high-risk patients with type 2 diabetes: an optical coherence tomography study. <i>Cardiovascular Diabetology</i> , 2020, 19, 192.	2.7	8
159	Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 2268.	3.8	540
160	Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58. <i>Circulation</i> , 2020, 142, 734-747.	1.6	44
161	Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the <sc>LEADER</sc> and <sc>SUSTAIN</sc> 6 trials. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2487-2492.	2.2	31
162	Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting. <i>Advanced Drug Delivery Reviews</i> , 2020, 159, 4-33.	6.6	113

#	ARTICLE	IF	CITATIONS
163	Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists: a Review for the General Cardiologist. <i>Current Cardiology Reports</i> , 2020, 22, 105.	1.3	3
164	Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME. <i>Journal of Hypertension</i> , 2020, 38, 1829-1840.	0.3	15
165	Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2020, 383, 1425-1435.	13.9	927
166	Two Tales: One Story. <i>Circulation</i> , 2020, 142, 2201-2204.	1.6	18
167	Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure. <i>Circulation</i> , 2020, 142, 1205-1218.	1.6	63
168	Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies. <i>Diabetes Care</i> , 2020, 43, 2713-2720.	4.3	15
169	Medicaid Expansion and Utilization of Antihyperglycemic Therapies. <i>Diabetes Care</i> , 2020, 43, 2684-2690.	4.3	13
170	Prescribing Paradigm Shift? Damned If You Do, Damned If You Don't. <i>Diabetes Care</i> , 2020, 43, 1991-1993.	4.3	0
171	Peptide YY (PYY) Is Associated with Cardiovascular Risk in Patients with Acute Myocardial Infarction. <i>Journal of Clinical Medicine</i> , 2020, 9, 3952.	1.0	5
172	Association of Long-term Change and Variability in Glycemia With Risk of Incident Heart Failure Among Patients With Type 2 Diabetes: A Secondary Analysis of the ACCORD Trial. <i>Diabetes Care</i> , 2020, 43, 1920-1928.	4.3	35
173	Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease. <i>JAMA Cardiology</i> , 2020, 5, 1182.	3.0	59
174	Science in a Time of Crisis. <i>Circulation</i> , 2020, 141, 1277-1278.	1.6	1
175	Cross-omics analysis revealed gut microbiome-related metabolic pathways underlying atherosclerosis development after antibiotics treatment. <i>Molecular Metabolism</i> , 2020, 36, 100976.	3.0	46
176	Association of Intensive Lifestyle Intervention, Fitness, and Body Mass Index With Risk of Heart Failure in Overweight or Obese Adults With Type 2 Diabetes Mellitus. <i>Circulation</i> , 2020, 141, 1295-1306.	1.6	67
177	Favorable COVID-19 course despite significant comorbidities in a ruxolitinib-treated patient with primary myelofibrosis. <i>European Journal of Haematology</i> , 2020, 105, 655-658.	1.1	24
178	Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial. <i>Diabetes Care</i> , 2020, 43, e108-e110.	4.3	34
179	Response to Comment on Segar et al. Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score. <i>Diabetes Care</i> 2019;42:2298-2306. <i>Diabetes Care</i> , 2020, 43, e26-e27.	4.3	2
180	Association between glycosylated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the TECOS randomized clinical trial. <i>European Journal of Heart Failure</i> , 2020, 22, 2026-2034.	2.9	18

#	ARTICLE	IF	CITATIONS
181	Segmental Bioelectrical Impedance Spectroscopy to Monitor Fluid Status in Heart Failure. <i>Scientific Reports</i> , 2020, 10, 3577.	1.6	19
182	Cardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: Analysis from the DECLARE-TIMI 58 trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1122-1131.	2.2	16
183	Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , 2020, 141, 1227-1234.	1.6	241
184	Response by Bergmark et al to Letter Regarding Article, "Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 Trial." <i>Circulation</i> , 2020, 141, e57-e58.	1.6	1
185	Trimethylamine N-Oxide and Adenosine Diphosphate-Induced Platelet Reactivity Are Independent Risk Factors for Cardiovascular and All-Cause Mortality. <i>Circulation Research</i> , 2020, 126, 660-662.	2.0	11
186	Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus. <i>Circulation</i> , 2020, 141, 843-862.	1.6	62
187	Empagliflozin improves left ventricular diastolic function of db/db mice. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2020, 1866, 165807.	1.8	36
188	Sharp rises in FGF23 and hypophosphatemia after intravenous iron administration do not cause myocardial damage. <i>Clinical Research in Cardiology</i> , 2020, 109, 1316-1318.	1.5	2
189	Contemporary Trends in Prescription of Dipeptidyl Peptidase-4 Inhibitors in the Context of US Food and Drug Administration Warnings of Heart Failure Risk. <i>American Journal of Cardiology</i> , 2020, 125, 1577-1581.	0.7	2
190	Reduction of cardiovascular risk in patients with T2DM by GLP-1 receptor agonists: a shift in paradigm driven by data from large cardiovascular outcome trials. <i>European Heart Journal</i> , 2020, 41, 3359-3362.	1.0	7
191	Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1357-1368.	2.2	26
192	Validation of distinct type 2 diabetes clusters and their association with diabetes complications in the DEVOTE, LEADER and SUSTAIN-6 cardiovascular outcomes trials. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1537-1547.	2.2	54
193	Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial. <i>Diabetes Care</i> , 2020, 43, 1803-1812.	4.3	44
194	Colocalization of plaque macrophages and calcification in coronary plaques as detected by optical coherence tomography predicts cardiovascular outcome. <i>Cardiology Journal</i> , 2020, 27, 303-306.	0.5	2
195	Ivabradine for the Therapy of Chronic Stable Angina Pectoris: a Systematic Review and Meta-Analysis. <i>Korean Circulation Journal</i> , 2020, 50, 773.	0.7	3
196	Management of patients with diabetes and heart failure with reduced ejection fraction: An international comparison. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 261-266.	2.2	7
197	Whole-Body Plethysmography and Blood Gas Analysis in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention. <i>Respiration</i> , 2019, 97, 24-33.	1.2	7
198	Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 3-14.	2.2	39

#	ARTICLE	IF	CITATIONS
199	Speckle Tracking Echocardiography and All-Cause and Cardiovascular Mortality Risk in Chronic Kidney Disease Patients. <i>Kidney and Blood Pressure Research</i> , 2019, 44, 690-703.	0.9	9
200	Long-term follow-up of intensive glycaemic control in type 2 diabetes. <i>Nature Reviews Cardiology</i> , 2019, 16, 517-518.	6.1	4
201	Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction. <i>Circulation</i> , 2019, 140, 1004-1014.	1.6	70
202	Novel plasma peptide markers involved in the pathology of CKD identified using mass spectrometric approach. <i>Journal of Molecular Medicine</i> , 2019, 97, 1451-1463.	1.7	10
203	Dose-dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2440-2449.	2.2	20
204	Aerobic Fitness and Adherence to Guideline-Recommended Minimum Physical Activity Among Ambulatory Patients With Type 2 Diabetes Mellitus. <i>Diabetes Care</i> , 2019, 42, 1333-1339.	4.3	38
205	The Dallas Bed Rest and Training Study. <i>Circulation</i> , 2019, 140, 1293-1295.	1.6	12
206	Associations between $\beta$ -blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease. <i>American Heart Journal</i> , 2019, 218, 92-99.	1.2	4
207	Incidence and predictors of pacemaker induced cardiomyopathy: A single-center experience. <i>Journal of Electrocardiology</i> , 2019, 57, 31-34.	0.4	16
208	Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS. <i>Cardiovascular Diabetology</i> , 2019, 18, 116.	2.7	14
209	Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019, 140, 1569-1577.	1.6	94
210	Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. <i>Lancet</i> , The, 2019, 394, 1169-1180.	6.3	155
211	Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1155.	3.8	423
212	Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction. <i>Circulation</i> , 2019, 140, 1463-1476.	1.6	279
213	Intrinsic calcification angle: a novel feature of the vulnerable coronary plaque in patients with type 2 diabetes: an optical coherence tomography study. <i>Cardiovascular Diabetology</i> , 2019, 18, 122.	2.7	16
214	Editorial: New Trends in Vascular Inflammation Research: From Biology to Therapy. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 102.	1.1	2
215	International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS. <i>American Heart Journal</i> , 2019, 218, 57-65.	1.2	4
216	FDA guidance on antihyperglycemic therapies for type 2 diabetes: One decade later. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1073-1078.	2.2	33

#	ARTICLE	IF	CITATIONS
217	Probing for Vulnerable Plaque in Patients With Diabetes Mellitus. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 124-125.	1.1	5
218	Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 606-617.	5.5	482
219	Identifying Familial Hypercholesterolemia Using a Blood Donor Screening Program With More Than 1 Million Volunteer Donors. <i>JAMA Cardiology</i> , 2019, 4, 685.	3.0	17
220	Antithrombotic treatment gap among patients with atrial fibrillation and type 2 diabetes. <i>International Journal of Cardiology</i> , 2019, 289, 58-62.	0.8	2
221	Significance of psychosocial factors in cardiology: update 2018. <i>Clinical Research in Cardiology</i> , 2019, 108, 1175-1196.	1.5	97
222	Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. <i>Circulation</i> , 2019, 139, 2516-2527.	1.6	224
223	Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019, 139, 2528-2536.	1.6	415
224	Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program. <i>Diabetes Care</i> , 2019, 42, 919-930.	4.3	51
225	Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk. <i>European Heart Journal</i> , 2019, 40, 2032-2043.	1.0	47
226	Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7). <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1625-1633.	2.2	18
227	Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10). <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1437-1444.	2.2	13
228	A novel transcatheter aortic valve with a form-fitting anchor for self-alignment: feasibility in a chronic preclinical model. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2019, 29, 8-14.	0.5	0
229	Relative Prognostic Importance and Optimal Levels of Risk Factors for Mortality and Cardiovascular Outcomes in Type 1 Diabetes Mellitus. <i>Circulation</i> , 2019, 139, 1900-1912.	1.6	108
230	Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019, 139, 2022-2031.	1.6	523
231	Cardiac FGF23: new insights into the role and function of FGF23 after acute myocardial infarction. <i>Cardiovascular Pathology</i> , 2019, 40, 47-54.	0.7	20
232	Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score. <i>Diabetes Care</i> , 2019, 42, 2298-2306.	4.3	157
233	Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 73-80.	0.8	56
234	Artificial intelligence supported patient self-care in chronic heart failure: a paradigm shift from reactive to predictive, preventive and personalised care. <i>EPMA Journal</i> , 2019, 10, 445-464.	3.3	96

#	ARTICLE	IF	CITATIONS
235	Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019, 140, 2108-2118.	1.6	22
236	Recognized Outstanding Reviewers for <i>Circulation</i> in 2019. <i>Circulation</i> , 2019, 140, 2047-2047.	1.6	0
237	Diabetes Mellitus and the Heart. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019, 127, S102-S104.	0.6	4
238	Position Paper on Lipid Therapy in Patients with Diabetes Mellitus. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019, 127, S97-S101.	0.6	0
239	Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. <i>Circulation</i> , 2019, 139, 351-361.	1.6	126
240	Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 69.	3.8	830
241	Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2019, 380, 347-357.	13.9	4,159
242	SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. <i>Lancet</i> , The, 2019, 393, 31-39.	6.3	1,958
243	Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial. <i>Circulation</i> , 2019, 139, 366-375.	1.6	32
244	Heart Failure Epidemiology in Patients With Diabetes Mellitus Without Coronary Heart Disease. <i>Journal of Cardiac Failure</i> , 2019, 25, 78-86.	0.7	22
245	Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial. <i>Circulation</i> , 2019, 139, 1384-1395.	1.6	205
246	Predictors for target lesion microcalcifications in patients with stable coronary artery disease: an optical coherence tomography study. <i>Clinical Research in Cardiology</i> , 2018, 107, 763-771.	1.5	28
247	The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)â€“TIMI 58 Trial. <i>American Heart Journal</i> , 2018, 200, 83-89.	1.2	117
248	<scp>DECLAREâ€“TIMI</scp> 58: Participantsâ€™ baseline characteristics. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1102-1110.	2.2	96
249	Opportunities and challenges of large-scale screening for atrial fibrillation. <i>Herzschrittmachertherapie Und Elektrophysiologie</i> , 2018, 29, 57-61.	0.3	4
250	Rationale, design, and baseline characteristics of the Cardiovascular safety and Renal Microvascular outcome study with LINagliptin (CARMELINAâ„®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk. <i>Cardiovascular Diabetology</i> , 2018, 17, 39.	2.7	70
251	Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patientsâ€“Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial. <i>American Heart Journal</i> , 2018, 202, 39-48.	1.2	15
252	The new SFB/TRR219 Research Centre. <i>European Heart Journal</i> , 2018, 39, 975-977.	1.0	11

#	ARTICLE	IF	CITATIONS
253	Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1379-1390.	1.2	50
254	DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. <i>Diabetologia</i> , 2018, 61, 58-65.	2.9	124
255	Sclerostin deficiency modifies the development of CKD-MBD in mice. <i>Bone</i> , 2018, 107, 115-123.	1.4	20
256	Hyperkalaemia in Heart Failure—Pathophysiology, Implications and Therapeutic Perspectives. <i>Current Heart Failure Reports</i> , 2018, 15, 390-397.	1.3	10
257	Cardiovascular Benefits of GLP-1 Receptor Agonism. <i>JACC Basic To Translational Science</i> , 2018, 3, 858-860.	1.9	10
258	Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association—European Society of Cardiology. <i>European Heart Journal</i> , 2018, 39, 4243-4254.	1.0	171
259	Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. <i>Lancet</i> , The, 2018, 392, 2269-2279.	6.3	70
260	Co-localization of plaque macrophages with calcification is associated with a more vulnerable plaque phenotype and a greater calcification burden in coronary target segments as determined by OCT. <i>PLoS ONE</i> , 2018, 13, e0205984.	1.1	29
261	Design and baseline characteristics of the eValuation of ERTugliflozin efficacy and Safety CardioVascular outcomes trial (VERTIS-CV). <i>American Heart Journal</i> , 2018, 206, 11-23.	1.2	171
262	Relation of plasma ceramides to visceral adiposity, insulin resistance and the development of type 2 diabetes mellitus: the Dallas Heart Study. <i>Diabetologia</i> , 2018, 61, 2570-2579.	2.9	67
263	Patterns of glucose-lowering medication use in patients with type 2 diabetes and heart failure. Insights from the Diabetes Collaborative Registry (DCR). <i>American Heart Journal</i> , 2018, 203, 25-29.	1.2	29
264	Pathways to Cardiorenal Complications in Type 2 Diabetes Mellitus. <i>Circulation</i> , 2018, 138, 7-9.	1.6	35
265	Effects of sodium glucose co-transporter 2 inhibitors on the kidney. <i>Diabetes and Vascular Disease Research</i> , 2018, 15, 375-386.	0.9	31
266	HbA1c and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study. <i>Diabetes Care</i> , 2018, 41, 1981-1990.	4.3	138
267	Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study. <i>Diabetes Care</i> , 2018, 41, 1970-1980.	4.3	170
268	Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2379-2388.	2.2	29
269	Myocardial infarction is sufficient to increase GLP-1 secretion, leading to improved left ventricular contractility and mitochondrial respiratory capacity. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2911-2918.	2.2	19
270	Should Metformin Remain First-Line Medical Therapy for Patients with Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease? An Alternative Approach. <i>Current Diabetes Reports</i> , 2018, 18, 64.	1.7	27



#	ARTICLE	IF	CITATIONS
271	Mechanisms of cardiovascular complications in chronic kidney disease: research focus of the Transregional Research Consortium SFB TRR219 of the University Hospital Aachen (RWTH) and the Saarland University. <i>Clinical Research in Cardiology</i> , 2018, 107, 120-126.	1.5	25
272	Long-Term Association of Low-Density Lipoprotein Cholesterol With Cardiovascular Mortality in Individuals at Low 10-Year Risk of Atherosclerotic Cardiovascular Disease. <i>Circulation</i> , 2018, 138, 2315-2325.	1.6	154
273	Glucagon-Like Peptide 1 and Its Cleavage Products Are Renoprotective in Murine Diabetic Nephropathy. <i>Diabetes</i> , 2018, 67, 2410-2419.	0.3	38
274	Reduced post-operative DPP4 activity associated with worse patient outcome after cardiac surgery. <i>Scientific Reports</i> , 2018, 8, 11820.	1.6	10
275	Empagliflozin Increases Cardiac Energy Production in Diabetes. <i>JACC Basic To Translational Science</i> , 2018, 3, 575-587.	1.9	263
276	Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. <i>New England Journal of Medicine</i> , 2018, 379, 1107-1117.	13.9	205
277	Assessing use of patient-focused pharmacotherapy in glycemic management through the Diabetes Collaborative Registry (DCR). <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 1035-1039.	1.2	3
278	Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2018, 379, 633-644.	13.9	888
279	Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial. <i>Clinical Cardiology</i> , 2018, 41, 1281-1288.	0.7	151
280	SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases. <i>Diabetologia</i> , 2018, 61, 2134-2139.	2.9	50
281	Impact of multidrug-resistant bacteria on outcome in patients with prolonged weaning. <i>BMC Pulmonary Medicine</i> , 2018, 18, 141.	0.8	13
282	The incretin hormone GIP is upregulated in patients with atherosclerosis and stabilizes plaques in ApoE <sup>-/-</sup> mice by blocking monocyte/macrophage activation. <i>Molecular Metabolism</i> , 2018, 14, 150-157.	3.0	38
283	Adipose tissue ATGL modifies the cardiac lipidome in pressure-overload-induced left ventricular failure. <i>PLoS Genetics</i> , 2018, 14, e1007171.	1.5	42
284	Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk. <i>JAMA Cardiology</i> , 2018, 3, 155.	3.0	78
285	Effect of lead position and orientation on electromagnetic interference in patients with bipolar cardiovascular implantable electronic devices. <i>Europace</i> , 2017, 19, euv458.	0.7	19
286	Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). <i>Diabetes Care</i> , 2017, 40, 494-501.	4.3	50
287	The association between HDL particle concentration and incident metabolic syndrome in the multi-ethnic Dallas Heart Study. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2017, 11, S175-S179.	1.8	17
288	Sex-Based Differences in Cardiometabolic Biomarkers. <i>Circulation</i> , 2017, 135, 544-555.	1.6	124

#	ARTICLE	IF	CITATIONS
289	Atrial Fibrillation, Type 2 Diabetes, and Non-Vitamin K Antagonist Oral Anticoagulants. JAMA Cardiology, 2017, 2, 442.	3.0	55
290	Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes. Lancet Diabetes and Endocrinology, 2017, 5, 391-402.	5.5	56
291	A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes. Cardiovascular Diabetology, 2017, 16, 13.	2.7	29
292	Range of Risk Factor Levels. Circulation, 2017, 135, 1522-1531.	1.6	102
293	In Vivo Study of Electromagnetic Interference With Pacemakers Caused by Everyday Electric and Magnetic Fields. Circulation, 2017, 135, 907-909.	1.6	23
294	Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. New England Journal of Medicine, 2017, 376, 1407-1418.	13.9	880
295	Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus. Circulation, 2017, 136, 1193-1203.	1.6	47
296	Longitudinal changes in serum 25-hydroxyvitamin D in the Dallas Heart Study. Clinical Endocrinology, 2017, 87, 242-248.	1.2	15
297	Slower Progress of Aortic Valve Calcification With Vitamin K Supplementation. Circulation, 2017, 135, 2081-2083.	1.6	114
298	Diabetes Mellitus and Heart Failure. American Journal of Medicine, 2017, 130, S40-S50.	0.6	118
299	Circulating annexin A5 levels are associated with carotid intima-media thickness but not coronary plaque composition. Diabetes and Vascular Disease Research, 2017, 14, 415-422.	0.9	4
300	Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. New England Journal of Medicine, 2017, 377, 723-732.	13.9	480
301	Cardiovascular adverse events in the drug-development program of bupropion for smoking cessation: A systematic retrospective adjudication effort. Clinical Cardiology, 2017, 40, 899-906.	0.7	3
302	Diabetes Mellitus and Heart Failure. American Journal of Cardiology, 2017, 120, S37-S47.	0.7	152
303	GLP-1 Levels Predict Mortality in Patients with Critical Illness as Well as End-Stage Renal Disease. American Journal of Medicine, 2017, 130, 833-841.e3.	0.6	44
304	Corrections needed to 2016 ESC guideline and AHA scientific statement on heart failure. Lancet Diabetes and Endocrinology, 2017, 5, 325-326.	5.5	6
305	Dual antiplatelet therapy in patients with diabetes and acute coronary syndromes managed without revascularization. American Heart Journal, 2017, 188, 156-166.	1.2	10
306	Multimodality Strategy for Cardiovascular Risk Assessment. Circulation, 2017, 135, 2119-2132.	1.6	75

#	ARTICLE	IF	CITATIONS
307	The PDE4 inhibitor roflumilast reduces weight gain by increasing energy expenditure and leads to improved glucose metabolism. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 496-508.	2.2	26
308	QT prolongation caused by insulin-induced hypoglycaemia – An interventional study in 119 individuals. <i>Diabetes Research and Clinical Practice</i> , 2017, 123, 165-172.	1.1	24
309	Unobtrusive Nocturnal Heartbeat Monitoring by a Ballistocardiographic Sensor in Patients with Sleep Disordered Breathing. <i>Scientific Reports</i> , 2017, 7, 13175.	1.6	31
310	The potential role and rationale for treatment of heart failure with sodium–glucose cotransporter 2 inhibitors. <i>European Journal of Heart Failure</i> , 2017, 19, 1390-1400.	2.9	139
311	Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point?. <i>Diabetes Care</i> , 2017, 40, 1144-1151.	4.3	50
312	Hypertension Control in Adults With Diabetes Mellitus and Recurrent Cardiovascular Events. <i>Hypertension</i> , 2017, 70, 907-914.	1.3	12
313	Residual Angina After Elective Percutaneous Coronary Intervention in Patients With Diabetes Mellitus. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	0.9	9
314	Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2017, 377, 2337-2348.	13.9	322
315	Quality of Care of the Initial Patient Cohort of the Diabetes Collaborative Registry <sup>Â</sup>. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	21
316	Effect of Empagliflozin on the Metabolic Signature of Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease. <i>Circulation</i> , 2017, 136, 969-972.	1.6	114
317	Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDRA® Research to Practice project. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 1637-1645.	0.8	109
318	Multi-centre study of whole-heart dynamic 3D cardiac magnetic resonance perfusion imaging for the detection of coronary artery disease defined by fractional flow reserve: gender based analysis of diagnostic performance. <i>European Heart Journal Cardiovascular Imaging</i> , 2017, 18, 1099-1106.	0.5	9
319	Leaving the Gluco-centric View. <i>Journal of the American College of Cardiology</i> , 2017, 70, 713-714.	1.2	0
320	Intra-procedural determination of viability by myocardial deformation imaging: a randomized prospective study in the cardiac catheter laboratory. <i>Clinical Research in Cardiology</i> , 2017, 106, 629-644.	1.5	3
321	Major Bleeding in Patients With Diabetes and Atrial Fibrillation Treated With New Oral Anticoagulants – Reply. <i>JAMA Cardiology</i> , 2017, 2, 1168.	3.0	3
322	Internet-based training of coronary artery patients: the Heart Cycle Trial. <i>Heart and Vessels</i> , 2017, 32, 408-418.	0.5	49
323	Impact of empagliflozin in patients with diabetes and heart failure. <i>Trends in Cardiovascular Medicine</i> , 2017, 27, 144-151.	2.3	21
324	Trimethylamine-N-oxide and Heart Failure With Reduced Versus Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2017, 70, 3202-3204.	1.2	62

#	ARTICLE	IF	CITATIONS
325	Heart failure. <i>Cardiovascular Endocrinology</i> , 2017, Publish Ahead of Print, 10-12.	0.8	2
326	Type 2 diabetes mellitus is associated with a lower fibrous cap thickness but has no impact on calcification morphology: an intracoronary optical coherence tomography study. <i>Cardiovascular Diabetology</i> , 2017, 16, 152.	2.7	46
327	Electrical impedance tomography for predicting failure of spontaneous breathing trials in patients with prolonged weaning. <i>Critical Care</i> , 2017, 21, 177.	2.5	35
328	Transcatheter aortic valve-in-valve implantation of a CoreValve in a JenaValve prosthesis: a case report. <i>Journal of Medical Case Reports</i> , 2017, 11, 256.	0.4	2
329	&lt;i>In vivo&/i> quantification of amyloid burden in TTR-related cardiac amyloidosis. <i>Intractable and Rare Diseases Research</i> , 2017, 6, 291-294.	0.3	1
330	Diabetes medications and cardiovascular outcome trials: Lessons learned. <i>Cleveland Clinic Journal of Medicine</i> , 2017, 84, 759-767.	0.6	13
331	Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes. <i>Circulation Research</i> , 2016, 118, 1830-1843.	2.0	51
332	Microdialysis and proteomics of subcutaneous interstitial fluid reveals increased galectin-1 in type 2 diabetes patients. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 998-1006.	1.5	23
333	Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus. <i>JAMA Cardiology</i> , 2016, 1, 126.	3.0	196
334	Revascularization Trends in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Presenting With Non-â€“ST Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 197-205.	0.9	52
335	Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. <i>European Heart Journal</i> , 2016, 37, 3192-3200.	1.0	142
336	Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 Journal</i> , 2016, 179, 175-183.	1.2	58
337	Bleeding risk following percutaneous coronary intervention in patients with diabetes prescribed dual anti-platelet therapy. <i>American Heart Journal</i> , 2016, 182, 111-118.	1.2	15
338	A Test in Context. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2479-2486.	1.2	23
339	Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS. <i>Diabetes Care</i> , 2016, 39, 2304-2310.	4.3	142
340	Predicting Adverse Outcomes After Myocardial Infarction Among Patients With Diabetes Mellitus. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 372-379.	0.9	22
341	Effect of treatment with rosiglitazone on high-sensitivity cardiac troponin levels among patients with type 2 diabetes mellitus. <i>Diabetes and Vascular Disease Research</i> , 2016, 13, 113-118.	0.9	3
342	Interleukin-6 predicts inflammation-induced increase of Glucagon-like peptide-1 in humans in response to cardiac surgery with association to parameters of glucose metabolism. <i>Cardiovascular Diabetology</i> , 2016, 15, 21.	2.7	30

#	ARTICLE	IF	CITATIONS
343	Heart Disease and Stroke Statisticsâ€™2016 Update. <i>Circulation</i> , 2016, 133, e38-360.	1.6	5,447
344	A Safety Evaluation of Empagliflozin for the Treatment of Type 2 Diabetes. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 393-402.	1.0	16
345	Prediction of Outcomes in Patients with Chronic Ischemic Cardiomyopathy by Layer-Specific Strain Echocardiography: A Proof of Concept. <i>Journal of the American Society of Echocardiography</i> , 2016, 29, 412-420.	1.2	47
346	Glycaemic control and cardiovascular risk factor management in patients with diabetes with and without coronary artery disease: insights from the diabetes mellitus status in Canada survey. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2016, 2, 277-284.	1.8	14
347	Association of Body Mass Index With Care and Outcomes in Patients With Atrial Fibrillation. <i>JACC: Clinical Electrophysiology</i> , 2016, 2, 355-363.	1.3	45
348	Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus. <i>Diabetes and Vascular Disease Research</i> , 2016, 13, 119-126.	0.9	122
349	Myocardial deformation by strain echocardiography identifies patients with acute coronary syndrome and non-diagnostic ECG presenting in a chest pain unit: a prospective study of diagnostic accuracy. <i>Clinical Research in Cardiology</i> , 2016, 105, 248-256.	1.5	29
350	Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c. <i>American Journal of Medicine</i> , 2016, 129, 340.e1-340.e8.	0.6	34
351	Epicardial adipose tissue in long-term hemodialysis patients: its association with vascular calcification and long-term development. <i>Journal of Nephrology</i> , 2016, 29, 241-250.	0.9	13
352	The vulnerable patient with chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 382-390.	0.4	33
353	Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial. <i>Diabetes Care</i> , 2015, 38, 696-705.	4.3	141
354	Comparison of Adipose Distribution Indices with Gold Standard Body Composition Assessments in the EMPA-REG H2H SU Trial: A Body Composition Sub-Study. <i>Diabetes Therapy</i> , 2015, 6, 635-642.	1.2	16
355	Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events. <i>Cardiovascular Diabetology</i> , 2015, 14, 57.	2.7	71
356	High-Risk Cardiovascular Patients: Clinical Features, Comorbidities, and Interconnecting Mechanisms. <i>Frontiers in Immunology</i> , 2015, 6, 591.	2.2	29
357	Heartbeat Cycle Length Detection by a Ballistocardiographic Sensor in Atrial Fibrillation and Sinus Rhythm. <i>BioMed Research International</i> , 2015, 2015, 1-10.	0.9	22
358	Feasibility of Bioelectrical Impedance Spectroscopy Measurement before and after Thoracentesis. <i>BioMed Research International</i> , 2015, 2015, 1-9.	0.9	7
359	Predicting Cardiovascular Risk in Type 2 Diabetes: the Heterogeneity Challenges. <i>Current Cardiology Reports</i> , 2015, 17, 607.	1.3	24
360	Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2015, 373, 232-242.	13.9	2,188

#	ARTICLE	IF	CITATIONS
361	Relation of Black Race Between High Density Lipoprotein Cholesterol Content, High Density Lipoprotein Particles and Coronary Events (from the Dallas Heart Study). <i>American Journal of Cardiology</i> , 2015, 115, 890-894.	0.7	36
362	Association between diabetes mellitus and angina after acute myocardial infarction: analysis of the TRIUMPH prospective cohort study. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 779-787.	0.8	15
363	High prevalence of elevated haemoglobin A1C among adolescent blood donors: Results from a voluntary screening programme including 31,546 adolescents. <i>Diabetes and Vascular Disease Research</i> , 2015, 12, 272-278.	0.9	6
364	PDE4 inhibition reduces neointima formation and inhibits VCAM-1 expression and histone methylation in an Epac-dependent manner. <i>Journal of Molecular and Cellular Cardiology</i> , 2015, 81, 23-33.	0.9	29
365	State-of-the-Art: Hypo-responsiveness to Oral Antiplatelet Therapy in Patients with Type 2 Diabetes Mellitus. <i>Current Cardiovascular Risk Reports</i> , 2015, 9, 4.	0.8	16
366	Metabolic Effects of Exercise Training Among Fitness-Nonresponsive Patients With Type 2 Diabetes: The HART-D Study. <i>Diabetes Care</i> , 2015, 38, 1494-1501.	4.3	62
367	Glucose-Lowering Medications and Angina Burden in Patients with Stable Coronary Disease: Results from the Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina (TERISA) Trial. <i>American Heart Journal</i> , 2015, 170, 753-759.e2.	1.2	5
368	Are patients with cardiac implants protected against electromagnetic interference in daily life and occupational environment?. <i>European Heart Journal</i> , 2015, 36, 1798-1804.	1.0	37
369	Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Climepiride in Type 2 Diabetes (CAROLINA <sup>®</sup> ). <i>Diabetes and Vascular Disease Research</i> , 2015, 12, 164-174.	0.9	197
370	Recognition of Incident Diabetes Mellitus During an Acute Myocardial Infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, 260-267.	0.9	16
371	Sodium-glucose co-transporter inhibition in the treatment of diabetes: Sweetening the pot. <i>Diabetes and Vascular Disease Research</i> , 2015, 12, 74-77.	0.9	3
372	Multicenter Evaluation of Dynamic Three-Dimensional Magnetic Resonance Myocardial Perfusion Imaging for the Detection of Coronary Artery Disease Defined by Fractional Flow Reserve. <i>Circulation: Cardiovascular Imaging</i> , 2015, 8, .	1.3	58
373	Identification of the Vasoconstriction-Inhibiting Factor (VIF), a Potent Endogenous Cofactor of Angiotensin II Acting on the Angiotensin II Type 2 Receptor. <i>Circulation</i> , 2015, 131, 1426-1434.	1.6	33
374	Serum levels of C-peptide are associated with coronary artery calcification in patients with rheumatoid arthritis. <i>Rheumatology International</i> , 2015, 35, 1541-1547.	1.5	5
375	Response to Letter Regarding Article, "Heart Failure, Saxagliptin and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial" <i>Circulation</i> , 2015, 132, e121-2.	1.6	61
376	Coronary Artery Calcium Improves Risk Classification in Younger Populations. <i>JACC: Cardiovascular Imaging</i> , 2015, 8, 1285-1293.	2.3	61
377	Soluble klotho and mortality: The Ludwigshafen Risk and Cardiovascular Health Study. <i>Atherosclerosis</i> , 2015, 242, 483-489.	0.4	38
378	Autoantibodies in dilated cardiomyopathy induce vascular endothelial growth factor expression in cardiomyocytes. <i>Biochemical and Biophysical Research Communications</i> , 2015, 465, 119-124.	1.0	5

#	ARTICLE	IF	CITATIONS
379	Severe myocardial ischaemia after neonatal arterial switch operation. <i>European Heart Journal</i> , 2015, 36, 3214-3214.	1.0	2
380	Target Organ Complications and Cardiovascular Events Associated With Masked Hypertension and White-Coat Hypertension. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2159-2169.	1.2	173
381	High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 288-293.	0.4	111
382	Abstract 273: HDL Particle Concentration Inversely Associates with Incident Metabolic Syndrome in the Multiethnic Dallas Heart Study. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, .	1.1	0
383	Homoarginine and Cardiovascular Outcome in the Population-Based Dallas Heart Study. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 2501-2507.	1.1	73
384	GLP-1 Secretion Is Increased by Inflammatory Stimuli in an IL-6-Dependent Manner, Leading to Hyperinsulinemia and Blood Glucose Lowering. <i>Diabetes</i> , 2014, 63, 3221-3229.	0.3	155
385	Glycated Hemoglobin in 14,850 Adolescent Blood Donors: A Pilot Screening Program: Table 1. <i>Diabetes Care</i> , 2014, 37, e3-e4.	4.3	6
386	Cardiovascular magnetic resonance profiling of coronary atherosclerosis: vessel wall remodelling and related myocardial blood flow alterations. <i>European Heart Journal Cardiovascular Imaging</i> , 2014, 15, 1400-1410.	0.5	7
387	The reliability of in-hospital diagnoses of diabetes mellitus in the setting of an acute myocardial infarction. <i>BMJ Open Diabetes Research and Care</i> , 2014, 2, e000046.	1.2	9
388	Is cardiorespiratory fitness a determinant of cardiomyopathy in the setting of type 2 diabetes?. <i>Diabetes and Vascular Disease Research</i> , 2014, 11, 343-351.	0.9	5
389	Electromagnetic Interference With Implantable Cardioverter-Defibrillators at Power Frequency. <i>Circulation</i> , 2014, 129, 441-450.	1.6	33
390	Effects of Ranolazine on Quality of Life Among Patients With Diabetes Mellitus and Stable Angina. <i>JAMA Internal Medicine</i> , 2014, 174, 1403.	2.6	20
391	Metformin in Patients With Type 2 Diabetes and Kidney Disease. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 2668.	3.8	474
392	Evaluation of a newly designed shirt-based ECG and breathing sensor for home-based training as part of cardiac rehabilitation for coronary artery disease. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 1332-1340.	0.8	21
393	Myocardial Deformation Imaging by Two-Dimensional Speckle-Tracking Echocardiography for Prediction of Global and Segmental Functional Changes after Acute Myocardial Infarction: A Comparison with Late Gadolinium Enhancement Cardiac Magnetic Resonance. <i>Journal of the American Society of Echocardiography</i> , 2014, 27, 249-257.	1.2	66
394	Patterns and Predictors of Intensive Statin Therapy Among Patients With Diabetes Mellitus After Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2014, 113, 1267-1272.	0.7	12
395	The Relationship of Body Mass and Fat Distribution With Incident Hypertension. <i>Journal of the American College of Cardiology</i> , 2014, 64, 997-1002.	1.2	209
396	Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial. <i>Circulation</i> , 2014, 130, 1579-1588.	1.6	594

#	ARTICLE	IF	CITATIONS
397	Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies. <i>Clinical Therapeutics</i> , 2014, 36, 1130-1146.	1.1	56
398	Contemporary Patterns of Discharge Aspirin Dosing After Acute Myocardial Infarction in the United States. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 701-707.	0.9	28
399	Coronary Revascularization Strategies in Patients With Diabetes and Multivessel Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1198-1201.	1.2	7
400	Fibroblast growth factor 23 (FGF23) and mortality: The Ludwigshafen Risk and Cardiovascular Health Study. <i>Atherosclerosis</i> , 2014, 237, 53-59.	0.4	79
401	Effectiveness of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina according to baseline hemoglobin A1c. <i>American Heart Journal</i> , 2014, 168, 457-465.e2.	1.2	17
402	Prevalence of glucose abnormalities among patients presenting with an acute myocardial infarction. <i>American Heart Journal</i> , 2014, 168, 466-470.e1.	1.2	58
403	Age- and Sex-Dependent Upper Reference Limits for the High-Sensitivity Cardiac Troponin T Assay. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1441-1448.	1.2	303
404	Type of $\beta$ -blocker use among patients with versus without diabetes after myocardial infarction. <i>American Heart Journal</i> , 2014, 168, 273-279.e1.	1.2	14
405	Novel insights into the mechanism of cell-based therapy after chronic myocardial infarction. <i>Discoveries</i> , 2014, 2, e9.	1.5	2
406	Abstract 16008: Improved Safety and Efficacy of a Novel Dual cRGD- and Everolimus-Coated Coronary Stent Compared to Everolimus-Eluting Stents in the Porcine Coronary Model. <i>Circulation</i> , 2014, 130, .	1.6	1
407	C-Peptide and Its Career from Innocent Bystander to Active Player in Diabetic Atherogenesis. <i>Current Atherosclerosis Reports</i> , 2013, 15, 339.	2.0	12
408	Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. <i>New England Journal of Medicine</i> , 2013, 369, 1317-1326.	13.9	3,017
409	Insulin Resistance and Risk for Incident Heart Failure $\hat{=}$ . <i>JACC: Heart Failure</i> , 2013, 1, 537-539.	1.9	8
410	Discordant effects of rosiglitazone on novel inflammatory biomarkers. <i>American Heart Journal</i> , 2013, 165, 609-614.	1.2	10
411	C-Peptide Levels Are Associated With Mortality and Cardiovascular Mortality in Patients Undergoing Angiography. <i>Diabetes Care</i> , 2013, 36, 708-714.	4.3	35
412	2013 ESC guidelines on the management of stable coronary artery disease. <i>European Heart Journal</i> , 2013, 34, 2949-3003.	1.0	3,915
413	Glucagon-Like Peptide-1 (9-36) Inhibits Chemokine-Induced Migration of Human CD4-Positive Lymphocytes. <i>PLoS ONE</i> , 2013, 8, e58445.	1.1	10
414	Abstract 481: Athero-metabolic and Inflammatory Alterations Promote In-stent Restenosis in ApolipoproteinE Deficient Rats. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, .	1.1	0



#	ARTICLE	IF	CITATIONS
415	Letter by McGuire and Aguilar Regarding Article, "Effect of Torcetrapib on Glucose, Insulin, and Hemoglobin A <sub>1c</sub> in Subjects in the Investigation of Lipid Level Management to Understand Its Impact in Atherosclerotic Events (ILLUMINATE) Trial" Circulation, 2012, 125, e427.	1.6	0
416	Commentary on "Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A meta-analysis" by Preiss et al.. Diabetes and Vascular Disease Research, 2012, 9, 78-78.	0.9	2
417	Drugs for type 2 diabetes mellitus: The imperative for cardiovascular outcome assessment. Diabetes and Vascular Disease Research, 2012, 9, 85-88.	0.9	4
418	Diabetes Mellitus and Trends in Hospital Survival After Myocardial Infarction, 1994 to 2006. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 791-797.	0.9	45
419	The effects of rosiglitazone on myocardial triglyceride content in patients with type 2 diabetes: A randomised, placebo-controlled trial. Diabetes and Vascular Disease Research, 2012, 9, 131-137.	0.9	16
420	Diabetes and the Cardiovascular System. , 2012, , 1392-1409.		4
421	Variability of clopidogrel response in patients with type 2 diabetes mellitus. Diabetes and Vascular Disease Research, 2011, 8, 245-253.	0.9	28
422	Adiponectin and cardiovascular risk profile in patients with type 2 diabetes mellitus: parameters associated with adiponectin complex distribution. Diabetes and Vascular Disease Research, 2011, 8, 190-194.	0.9	24
423	Resolving drug effects from class effects among drugs for type 2 diabetes mellitus: more support for cardiovascular outcome assessments. European Heart Journal, 2011, 32, 1832-1834.	1.0	24
424	Assessment of cardiac structure and function in patients without and with peripheral oedema during rosiglitazone treatment. Diabetes and Vascular Disease Research, 2011, 8, 101-108.	0.9	7
425	Biomarkers in Clinical Trials. Circulation, 2011, 124, 663-665.	1.6	5
426	A commentary on Diabetic and non-diabetic patients with left main and/ or three-vessel coronary artery disease: Comparison of outcomes with cardiac surgery and paclitaxel-eluting stents by Banning AP et al*. Diabetes and Vascular Disease Research, 2011, 8, 173-173.	0.9	2
427	Glucagon-like peptide-1(1-37) inhibits chemokine-induced migration of human CD4-positive lymphocytes. Cellular and Molecular Life Sciences, 2010, 67, 3549-3555.	2.4	33
428	The Peroxisome Proliferator-Activated Receptor- $\beta$ Agonist Rosiglitazone Increases Bone Resorption in Women with Type 2 Diabetes: A Randomized, Controlled Trial. Calcified Tissue International, 2010, 86, 343-349.	1.5	47
429	The effect of intensive glucose control on all-cause and cardiovascular mortality, myocardial infarction and stroke in persons with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes and Vascular Disease Research, 2010, 7, 119-130.	0.9	52
430	Diabetes and Heart Failure in Patients With Coronary Disease: Separating Markers From Mediators. Diabetes Care, 2010, 33, 2120-2122.	4.3	5
431	Association of Troponin T Detected With a Highly Sensitive Assay and Cardiac Structure and Mortality Risk in the General Population. JAMA - Journal of the American Medical Association, 2010, 304, 2503.	3.8	936
432	Associations of Four Circulating Chemokines with Multiple Atherosclerosis Phenotypes in a Large Population-Based Sample: Results from the Dallas Heart Study. Journal of Interferon and Cytokine Research, 2010, 30, 339-347.	0.5	36

#	ARTICLE	IF	CITATIONS
433	Diabetes mellitus in patients with myocardial infarction complicated by heart failure: a "low ejection fraction" equivalent?. <i>European Journal of Heart Failure</i> , 2010, 12, 1156-1158.	2.9	1
434	Randomized comparison of the effects of rosiglitazone vs. placebo on peak integrated cardiovascular performance, cardiac structure, and function. <i>European Heart Journal</i> , 2010, 31, 2262-2270.	1.0	28
435	Circulating lymphotoxin $\beta_2$ receptor and atherosclerosis: Observations from the Dallas Heart Study. <i>Atherosclerosis</i> , 2010, 212, 601-606.	0.4	18
436	Association Between Circulating Soluble Receptor for Advanced Glycation End Products and Atherosclerosis. <i>Diabetes Care</i> , 2009, 32, 1218-1220.	4.3	83
437	Evaluation of the Glycometabolic Effects of Ranolazine in Patients With and Without Diabetes Mellitus in the MERLIN-TIMI 36 Randomized Controlled Trial. <i>Circulation</i> , 2009, 119, 2032-2039.	1.6	144
438	Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications. <i>Diabetes and Vascular Disease Research</i> , 2009, 6, 7-14.	0.9	72
439	Platelet perturbations in diabetes: implications for cardiovascular disease risk and treatment. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 541-549.	0.6	22
440	Differential Associations Between Soluble Cellular Adhesion Molecules and Atherosclerosis in the Dallas Heart Study. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 1684-1690.	1.1	39
441	The effect of rosiglitazone on integrated cardiovascular performance, cardiac structure, function and myocardial triglyceride: trial design and rationale. <i>Diabetes and Vascular Disease Research</i> , 2009, 6, 43-50.	0.9	13
442	Cardiovascular disease and type 2 diabetes mellitus: Regulating glucose and regulating drugs. <i>Current Cardiology Reports</i> , 2009, 11, 258-263.	1.3	29
443	The association between peptidoglycan recognition protein-1 and coronary and peripheral atherosclerosis: Observations from the Dallas Heart Study. <i>Atherosclerosis</i> , 2009, 203, 569-575.	0.4	41
444	Effects of the Thiazolidinedione Medications on Micro- and Macrovascular Complications in Patients with Diabetes"Update 2008. <i>Cardiovascular Drugs and Therapy</i> , 2008, 22, 233-240.	1.3	22
445	Cardiomyopathy in Type 2 Diabetes. <i>Herz</i> , 2008, 33, 184-190.	0.4	46
446	New Drugs for the Treatment of Diabetes Mellitus. <i>Circulation</i> , 2008, 117, 440-449.	1.6	114
447	New Drugs for the Treatment of Diabetes. <i>Circulation</i> , 2008, 117, 574-584.	1.6	181
448	Management of Coronary Artery Disease in Type 2 Diabetes Mellitus. , 2008, , 289-319.		1
449	Blocking the renin-angiotensin-aldosterone system to prevent diabetes mellitus. <i>Diabetes and Vascular Disease Research</i> , 2008, 5, 59-66.	0.9	38
450	Metformin in Heart Failure. <i>Diabetes Care</i> , 2007, 30, e129-e129.	4.3	56

#	ARTICLE	IF	CITATIONS
451	Increased cardiovascular risk associated with diabetes in Dallas County. <i>American Heart Journal</i> , 2006, 151, 1087-1093.	1.2	6
452	Underuse of evidence-based treatment partly explains the worse clinical outcome in diabetic patients with acute coronary syndromes. <i>American Heart Journal</i> , 2006, 152, 676-683.	1.2	43
453	The Editor's Roundtable: Diabetes Mellitus and Coronary Heart Disease. <i>American Journal of Cardiology</i> , 2006, 98, 842-856.	0.7	4
454	Thiazolidinediones and risk for atherosclerosis: pleiotropic effects of PPAR $\gamma$ agonism. <i>Diabetes and Vascular Disease Research</i> , 2006, 3, 65-71.	0.9	37
455	Relationship Between C-Reactive Protein and Subclinical Atherosclerosis. <i>Circulation</i> , 2006, 113, 38-43.	1.6	184
456	Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events. <i>European Heart Journal</i> , 2005, 26, 1255-1261.	1.0	264
457	How aggressive should lipid lowering be among patients with acute coronary syndromes?. <i>Current Cardiology Reports</i> , 2005, 7, 283-287.	1.3	0
458	Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?. <i>Diabetes and Vascular Disease Research</i> , 2005, 2, 61-66.	0.9	70
459	Urinary tract infection in patients with acute coronary syndrome: A potential systemic inflammatory connection. <i>American Heart Journal</i> , 2005, 149, 1062-1065.	1.2	25
460	Management of Diabetic Dyslipidemia. <i>American Journal of Cardiovascular Drugs</i> , 2005, 5, 83-91.	1.0	9
461	Diabetes Mellitus and Cardiovascular Disease. <i>Herz</i> , 2004, 29, 456-62.	0.4	18
462	Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes. <i>American Heart Journal</i> , 2004, 147, 246-252.	1.2	67
463	Influence of the Bypass Angioplasty Revascularization Investigation National Heart, Lung, and Blood Institute Diabetic Clinical Alert on Practice Patterns. <i>Circulation</i> , 2003, 107, 1864-1870.	1.6	27
464	Early Statin Initiation and Outcomes in Patients With Acute Coronary Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2002, 287, 3087.	3.8	136
465	A 30-Year Follow-Up of the Dallas Bed Rest and Training Study. <i>Circulation</i> , 2001, 104, 1350-1357.	1.6	163
466	A 30-Year Follow-Up of the Dallas Bed Rest and Training Study. <i>Circulation</i> , 2001, 104, 1358-1366.	1.6	196
467	PPAR $\gamma$ Activators Inhibit Tissue Factor Expression and Activity in Human Monocytes. <i>Circulation</i> , 2001, 103, 213-219.	1.6	177
468	PPAR $\gamma$ Activation in Human Endothelial Cells Increases Plasminogen Activator Inhibitor Type-1 Expression. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 546-551.	1.1	355

#	ARTICLE	IF	CITATIONS
469	PPAR $\gamma$ Activators Inhibit Cytokine-Induced Vascular Cell Adhesion Molecule-1 Expression in Human Endothelial Cells. <i>Circulation</i> , 1999, 99, 3125-3131.	1.6	584
470	Peroxisome Proliferator-Activated Receptor Gamma Activators Inhibit Gene Expression and Migration in Human Vascular Smooth Muscle Cells. <i>Circulation Research</i> , 1998, 83, 1097-1103.	2.0	565
471	Recurrent pericardial effusion and tamponade after epicardial pacemaker lead placement: a case report. <i>European Heart Journal - Case Reports</i> , 0, , .	0.3	0